Govt Job: For Pharmacist in Drug De-Addiction Centre at PGIMER

The PGIMER owes its inception to the vision of late Sardar Partap Singh Kairon, the then Chief Minister of Punjab and the distinguished medical educationists of the then combined state of Punjab, supported by the first Prime Minister of India Pt. Jawahar Lal Nehru who considered the institutions of scientific knowledge as temples of learning and the places of pilgrimage.

Post : Pharmacist

Applications are invited from the eligible candidates for filling up 1 post of Pharmacist. The detail of post and eligibility / criteria for filling up the said post is given as under.

Age : Up to 30 years

Emoluments : As per D.C Rate of Chandigarh Administration presently Rs 23,393/-

Qualifications :
Essentials:
1. Senior Secondary with Science or its equivalent from a recognised University/Board.

II. Degree in Pharmacy from a recognized institution/university.

III. Should be a registered Pharmacist under the Pharmacy Act 1948.
Desirable :

1. One year experience in dispensing and/or storage and dispensing of drugs in a reputed hospital or Institute or in a drug store of a pharmaceutical concern.

The applicants are required to submit their Bio-data (with self-attested photo copies of all the supporting documents & one photograph) by in the office of Drug De-addiction & Treatment Centre, PGIMER, Chandigarh.

And to be appeared for personal interview along with original certificate on 10/03/2022 at 9:30 am in Drug De-Addiction & Treatment Centre, PGIMER, Chandigarh.

If large numbers of applications are received a written test will be conducted.

No separate interview letters will be sent. No TA/DA will be paid.

Related Posts

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March